Bixiye
QP51-23 Commercial Pharmacy Benefit Exclusion for Aponvie™, Iheezo™, Omisirge®, and Qalsody™
Taariikhda wax ku ool ah ee barnaamijka: Jun 14, 2023
Natiijooyinka Raadinta
Soo bandhiga 1411 - 1420 ee natiijooyinka 3685
Bixiye
QP52-23 MHCP Pharmacy Benefit Exclusion for Iheezo™, Omisirge®, and Qalsody™
Taariikhda wax ku ool ah ee barnaamijka: Jun 14, 2023
Bixiye
QP53-23 Commercial Pharmacy Benefit Update: Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective August 1, 2023
Taariikhda wax ku ool ah ee barnaamijka: Jun 14, 2023
Bixiye
Furoscix® (furosemide) - Medicaid
Prior Authorization, Quantity Limit
Taariikhda uu dhaqangalayo Barnaamijka: Des 01, 2024
Bixiye
Antidepressant - Medicaid
Quantity Limit
Taariikhda wax ku ool ah ee barnaamijka: Jun 01, 2025
Bixiye
QP48-23 Update for New to Market Medical Drugs: delandistrogene moxeparvovec and epcoritamab
Taariikhda wax ku ool ah ee barnaamijka: Jun 14, 2023
Bixiye
QP49-23 Register for Webinar | Trauma-Informed Care 101 | Thursday, June 29, 5-6:30 pm
Taariikhda wax ku ool ah ee barnaamijka: Jun 14, 2023
Bixiye
QP50-23 Fetal Alcohol Syndrome Education Opportunity
Taariikhda wax ku ool ah ee barnaamijka: Jun 14, 2023
Bixiye
P50-23 eviCore Healthcare Specialty Utilization Management (UM) Program: Medical Oncology Drug Prior Authorization Updates
Taariikhda dhaqangalka Barnaamijka: Jul 03, 2023
Bixiye
P51-23 Medical Policy Updates: Coupe Health and Self-Funded Benefit Plans managed by Blue Cross and Blue Shield of Alabama
Taariikhda dhaqangalka Barnaamijka: Jul 03, 2023